Negative Predictive Value of Surveillance PET/CT in Head and Neck Squamous Cell Cancer
Open Access
- 2 May 2013
- journal article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (8), 1632-1636
- https://doi.org/10.3174/ajnr.a3494
Abstract
BACKGROUND AND PURPOSE: Optimizing the utilization of surveillance PET/CT in treated HNSCC is an area of ongoing research. Our aim was to determine the negative predictive value of PET/CT in patients with treated head and neck squamous cell cancer and to determine whether negative PET/CT reduces the need for further imaging surveillance. MATERIALS AND METHODS: We evaluated patients with treated HNSCC who underwent posttreatment surveillance PET/CT. During routine clinical readouts, scans were categorized as having negative, probably negative, probably malignant, or malignant findings. We followed patients clinically and radiographically for at least 12 months from their last PET/CT (mean, 26 months; median, 28 months; range, 12–89 months) to determine recurrence rates. All suspected recurrences underwent biopsy for confirmation. RESULTS: Five hundred twelve patients (1553 scans) were included in the study. Two hundred fourteen patients had at least 1 PET/CT with negative findings. Of the 214 patients with a scan with negative findings, 19 (9%) eventually experienced recurrence, resulting in a NPV of 91%. In addition, a subgroup of 114 patients with 2 consecutive PET/CT examinations with negative findings within a 6-month period was identified. Only 2 recurrences were found in this group, giving a NPV of 98%. CONCLUSIONS: In patients treated for HNSCC, a single PET/CT with negative findings carries a NPV of 91%, which is not adequate to defer further radiologic surveillance. Two consecutive PET/CT examinations with negative findings within a 6-month period, however, resulted in a NPV of 98%, which could obviate further radiologic imaging in the absence of clinical signs of recurrence.Keywords
This publication has 15 references indexed in Scilit:
- Temporal patterns of head and neck squamous cell carcinoma recurrence with positron‐emission tomography/computed tomography monitoringThe Laryngoscope, 2012
- Clinical Utility of18F-FDG PET/CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck CancerJournal of Nuclear Medicine, 2008
- Indications for PET/CT in the Head and NeckOtolaryngologic Clinics of North America, 2008
- Deferring Planned Neck Dissection Following Chemoradiation for Stage IV Head and Neck Cancer: The Utility of PET‐CTThe Laryngoscope, 2007
- Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancersInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Head and Neck Malignancy: Is PET/CT More Accurate than PET or CT Alone?Radiology, 2005
- Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancerHead & Neck, 2004
- Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary reportInternational Journal of Radiation Oncology*Biology*Physics, 2004
- FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Positron Emission Tomography in the Early Follow-up of Advanced Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2004